MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?
IntroductionExpression of PD-L1 on cancer cells is the only validated predictive factor for immunotherapy in NSCLC (Non-Small Cell Lung Cancer) patients. However, on this basis, it is difficult to predict the occurrence of resistance to immune checkpoint inhibitors (ICIs). MicroRNAs are widely studi...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-02-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1344858/full |
| _version_ | 1797295218381291520 |
|---|---|
| author | Anna Grenda Barbara Kuźnar-Kamińska Ewa Kalinka Paweł Krawczyk Marek Sawicki Agata Filip Izabela Chmielewska Małgorzata Frąk Natalia Krzyżanowska Janusz Milanowski |
| author_facet | Anna Grenda Barbara Kuźnar-Kamińska Ewa Kalinka Paweł Krawczyk Marek Sawicki Agata Filip Izabela Chmielewska Małgorzata Frąk Natalia Krzyżanowska Janusz Milanowski |
| author_sort | Anna Grenda |
| collection | DOAJ |
| description | IntroductionExpression of PD-L1 on cancer cells is the only validated predictive factor for immunotherapy in NSCLC (Non-Small Cell Lung Cancer) patients. However, on this basis, it is difficult to predict the occurrence of resistance to immune checkpoint inhibitors (ICIs). MicroRNAs are widely studied as biomarkers of cancers. Our study was designed to determine whether microRNAs can be sensitive predictive factors in the qualification of NSCLC patients to first-line immunotherapy or chemoimmunotherapy.Material and methodsThe two-stage research on validation group (n=20) and study group (n=35) of patients with advanced NSCLC was conducted. Analysis of microRNAs expression by qPCR in plasma collected prior to the start of immunotherapy (pembrolizumab) or chemoimmunotherapy (combination of pembrolizumab with chemotherapy) was made. Broad-spectrum analysis of microRNAs expression was used in the studied group. Three microRNAs selected in that group as important for the effectiveness of ICIs were then examined in the validation group.ResultsIn the studied group, significantly higher expression of miRNA-126-3p, miR-144-3p and miR-146-5p was observed in patients with long PFS compared to those with short PFS. In the validation group, low miRNA-126 expression indicated lower median progression-free survival and overall survival (2.3 vs. 5.0 months and 5.2 vs 11.2, respectively). These patients had a significantly higher risk of progression (HR= 2.92, 95% CI: 1.01 to 8.40, p=0.04) and death (HR=3.64, 95% CI: 1.22 to 10.84, p=0.02).ConclusionOur study showed that the expression of miR-126 in blood plasma may be a predictive factor for the effectiveness of first-line immunotherapy or chemoimmunotherapy in advanced NSCLC patients. |
| first_indexed | 2024-03-07T21:43:34Z |
| format | Article |
| id | doaj.art-77b9ec4544904e9a85981dd728a30d2d |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-03-07T21:43:34Z |
| publishDate | 2024-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-77b9ec4544904e9a85981dd728a30d2d2024-02-26T04:23:42ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-02-011510.3389/fimmu.2024.13448581344858MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients?Anna Grenda0Barbara Kuźnar-Kamińska1Ewa Kalinka2Paweł Krawczyk3Marek Sawicki4Agata Filip5Izabela Chmielewska6Małgorzata Frąk7Natalia Krzyżanowska8Janusz Milanowski9Department of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, PolandDepartment of Pulmonology, Allergology and Pulmonary Oncology, Poznan University of Medical Sciences, Poznań, PolandDepartment of Oncology, Polish Mother’s Memorial Hospital Research Institute, Łódź, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, PolandDepartment of Thoracic Surgery, Medical University of Lublin, Lublin, PolandDepartment of Cancer Genetics with Department of Cancer Genetics with Cytogenetics Laboratory, Medical University in Lublin, Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, PolandDepartment of Pneumonology, Oncology and Allergology, Medical University of Lublin, Lublin, PolandIntroductionExpression of PD-L1 on cancer cells is the only validated predictive factor for immunotherapy in NSCLC (Non-Small Cell Lung Cancer) patients. However, on this basis, it is difficult to predict the occurrence of resistance to immune checkpoint inhibitors (ICIs). MicroRNAs are widely studied as biomarkers of cancers. Our study was designed to determine whether microRNAs can be sensitive predictive factors in the qualification of NSCLC patients to first-line immunotherapy or chemoimmunotherapy.Material and methodsThe two-stage research on validation group (n=20) and study group (n=35) of patients with advanced NSCLC was conducted. Analysis of microRNAs expression by qPCR in plasma collected prior to the start of immunotherapy (pembrolizumab) or chemoimmunotherapy (combination of pembrolizumab with chemotherapy) was made. Broad-spectrum analysis of microRNAs expression was used in the studied group. Three microRNAs selected in that group as important for the effectiveness of ICIs were then examined in the validation group.ResultsIn the studied group, significantly higher expression of miRNA-126-3p, miR-144-3p and miR-146-5p was observed in patients with long PFS compared to those with short PFS. In the validation group, low miRNA-126 expression indicated lower median progression-free survival and overall survival (2.3 vs. 5.0 months and 5.2 vs 11.2, respectively). These patients had a significantly higher risk of progression (HR= 2.92, 95% CI: 1.01 to 8.40, p=0.04) and death (HR=3.64, 95% CI: 1.22 to 10.84, p=0.02).ConclusionOur study showed that the expression of miR-126 in blood plasma may be a predictive factor for the effectiveness of first-line immunotherapy or chemoimmunotherapy in advanced NSCLC patients.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1344858/fullmicroRNAimmunotherapyanti-PD-1NSCLCmiRNA |
| spellingShingle | Anna Grenda Barbara Kuźnar-Kamińska Ewa Kalinka Paweł Krawczyk Marek Sawicki Agata Filip Izabela Chmielewska Małgorzata Frąk Natalia Krzyżanowska Janusz Milanowski MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients? Frontiers in Immunology microRNA immunotherapy anti-PD-1 NSCLC miRNA |
| title | MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients? |
| title_full | MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients? |
| title_fullStr | MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients? |
| title_full_unstemmed | MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients? |
| title_short | MicroRNA-126 selected with broad-spectrum analysis of microRNAs – a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced NSCLC patients? |
| title_sort | microrna 126 selected with broad spectrum analysis of micrornas a new predictive factor for the effectiveness of immunotherapy or chemoimmunotherapy in advanced nsclc patients |
| topic | microRNA immunotherapy anti-PD-1 NSCLC miRNA |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1344858/full |
| work_keys_str_mv | AT annagrenda microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT barbarakuznarkaminska microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT ewakalinka microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT pawełkrawczyk microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT mareksawicki microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT agatafilip microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT izabelachmielewska microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT małgorzatafrak microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT nataliakrzyzanowska microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients AT januszmilanowski microrna126selectedwithbroadspectrumanalysisofmicrornasanewpredictivefactorfortheeffectivenessofimmunotherapyorchemoimmunotherapyinadvancednsclcpatients |